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1. Introduction 
Tunicamycin is a glucosamine containing antibiotic 
[ 1 ] which inhibits the biosynthesis of glycoproteins in 
both yeast [2,3] and mammalian cells [4,5] by 
preventing the formation of dolichyl-pyrophosphoryl- 
N-acetylglucosamine. This intermediate is involved 
in the early stages of the biosynthetic pathway 
leading to glycosylation of the various proteins. In 
bacterial systems tunicamycin was shown to inhibit 
the incorporation of glucosamine into macromolecular 
material, presumably the wall of the organisms [6] . 
More recently Bettinger and Young [7] reported the 
inhibition of peptidoglycan synthesis in Bacillus 
subtilis 168 and that the site of action of the antibiotic 
was the formation of the second lipid intermediate 
undecaprenyl-P-P-N-acetylmuramyl-(pentapeptide)- 
N-acetylglucosamine. In the biosynthesis of peptido- 
glycan this intermediate is formed by the transfer of 
N-acetylglucosamine from UDP-N-acetylglucosamine 
to undecaprenyl-P-P-N-acetylmuramyl-pentapeptide. 
In addition they also observed inhibition by tunica- 
mycin of the formation of an additional lipid inter- 
mediate in which one or several N-acetylglucosamine 
residues are pyrophosphate-linked to undecaprenol. 
The function of this intermediate which is also present 
in other bacilli remains unclear. 
In contrast to the above observations Tamura et al. 
[B] using particulate enzyme preparations from 
Micrococcus lysodeikticus (luteus), concluded that 
tunicamycin inhibited peptidoglycan synthesis by 
preventing the formation of the first lipid intermediate, 
undecaprenyl-P-P-N-acetylmuramyl pentapeptide. 
The present study, which was initiated before the 
publicatiori of Tamura et al. [B] was undertaken to 
determine at what site tunicamycin inhibited peptido- 
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glycan synthesis. The results obtained both support 
and extend to several other bacteria, their [B] conclu- 
sion that tunicamycin acts by inhibiting phospho-ni’- 
acetylmuramyl pentapeptide translocase, the initial 
membrane-bound reaction in peptidoglycan synthesis. 
2. Materials and methods 
The bacteria used were Bacillus lichen&rmis 94, 
a /3-lactamase and N-acetylmuramyl-L-alanine amidase 
deficient mutant derived from B. licheniformis 6346 
[9], B. subtilis 168 trp thy, B. subtilis W23, Micro- 
coccus luteus NCTC 2665 and Staphylococcus aureus 
H. 
Organisms were grown at 35°C with shaking in a 
medium containing tryptone 1% (w/v), yeast extract 
1% (w/v) (both from Difco) and KHzP04 0.5% (w/v). 
Glucose, sterilized separately was added to a final 
concentration of 0.4% (w/v). Cultures were harvested 
in the exponential phase of growth, A600 1 S-2.0, 
and the bacteria were washed once with 50 mM Tris 
(hydroxymethyl) amino methane-Tris-HCl buffer, 
pH 7.8, containing 60 mM MgClz and 1 mM dithio- 
threitol. 
Membranes were prepared from the washed orga- 
nisms by grinding with alumina and differential 
centrifugation as described previously [9] . Membrane 
preparations to be used for the determination of 
phospho-N-acetylmuramyl pentapeptide translocase 
were first treated to remove endogenous lipid inter- 
mediates by prior incubation with uridineS’-mono- 
phosphate as described by Hammes and Neuhaus 
DOI * 
The activity of the translocase was determined 
both by utilizing the exchange assay of Hammes 
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and Neuhaus [lo] and also in a transfer assay which 
measured the formation of butan-l-01 soluble radio- 
activity from UDP-N-acetyl-muramyl-(diamino [3H] 
pimelic acid)-pentapeptide. The reaction mixture 
contained in total vol. 50 &SO mM Tris-HCl pH 7.8, 
0.21 M KCl, 42 PM MgClz, alkaline phosphatase 
(Boehringer) 5pg, 0.17 mM UDP-MurAc-[3H]DAP- 
pentapeptide (17.4 mCi/mmol) and membrane 
preparation (250-350 fig protein). This was incu- 
bated for 2 min at 25°C and the reaction was then 
stopped by the addition of butan-l-01 6M-pyridinium 
acetate, pH 4.2 (2: 1 v/v) (300 11) and water (250 ~1). 
After mixing and centrifuging the organic phase was 
removed and the aqueous phase re-extracted with 
butan-l-01 (water saturated) (2 X 400 4). The 
combined extracts were backwashed with water 
(butanol-l-01 saturated) (2 X 1 ml) and air-dried in 
vials prior to the determination of radioactivity. 
Formation of the glucosamine-containing lipid 
was determined in reaction mixtures containing in 
total vol. 50 ~1, 50 mM Tris-HCl, pH 7.8,60 mM 
MgC12, 1mM dithiothreitol, 0.15 mM UDP-[‘4C] 
GlcNAc (4.4 mCi/mmol) and membrane preparation 
(250-350 ,ug protein). After incubation for 10 min 
at 25’C the reaction was stopped and the lipid-linked 
[‘4C]GlcNAc isolated either by the procedure out- 
lined above in the transfer assay of translocase activity 
or as described by Bettinger and Young [7] . Identical 
results were obtained using either technique. 
The effects of tunicamycin on the synthesis of 
peptidoglycan and 1,3-poly(glycero1 phosphate) 
teichoic acid were determined using membrane +wall 
preparations of B. licheniformis 94 as previously 
described [ 1 l] . After incubation at 28°C for 30 min 
the reactions were terminated by addition of sodium 
dodecyl sulphate (10% w/v) and the wall (SDS- 
insoluble) and membrane (SDS-soluble) fractions 
prepared [ 1 l] . 
Tunicamycin, supplied by Dr G. Tamura, University 
of Tokyo, was the kind gift of Professor A. H. Rose, 
Unive:sity of Bath. UDP-MurAc pentapeptide labelled 
with diamino [ 3H] pimelic acid (400 mCi/mmol) and 
CDP- [jH] glycerol (100 mCi/mmol) were prepared as 
described previously [1 l] UDP-N-acetyl [14C] gluco- 
samine (300 mCi/mmol) and [ i4C]uridineJ’-mono- 
phosphate (264 mCi/mmol) were purchased from the 
Radiochemical Centre, Amersham, Bucks. Non-radio- 
active UDP-MurAc pentapeptide was isolated from 
152 
Mg”-deprived cultures of B. licheniformis and the 
corresponding lysine-containing UDP-MurAc penta- 
peptide was the gift of Dr A. Weston, University of 
Liverpool. Other non-radioactive precursors were 
purchased from Sigma. 
3. Results and discussion 
With the exception of S. aureus H which grew in 
the highest concentration of antibiotic tested (50 pg/ 
ml) tunicamycin inhibited growth of all the other 
bacteria used in this study, although there were 
marked ifferences in the amount of antibiotic 
required to effect this inhibition. Growth of both 
B. subtilis 168 and W23 was inhibited at antibiotic 
concentrations of 0.2 and 0.5 pg/ml whereas 10 c(g/ 
ml and 50 &/ml were required to inhibit the growth 
of B. licheniformis 94 and M. luteus, respectively. 
The effect of tunicamycin on the in vitro synthesis 
of both peptidoglycan and teichoic acid was deter- 
mined using membrane +wall preparations of
B. licheniformis 94. Peptidoglycan synthesis was 
inhibited by 59% at an antibiotic concentration of 
10 pg/ml (fig.1). At lower concentrations (l-2 pg/ml) 
a stimulation of the synthesis of cross-linked (SDS- 
insoluble) peptidoglycan was obtained although there 
was no concomitant change in the synthesis of 
uncross-linked (SDS-soluble) peptidoglycan. Tunica- 
mycin also inhibited the synthesis of wall-associated 
(SDS-insoluble) 1,3-poly(glycero1 phosphate) teichoic 
acid. In this case the lower concentrations of anti- 
biotic did not stimulate the formation of either SDS- 
insoluble or soluble polymeric material. At the higher 
antibiotic concentrations the amount of diamino 
[3H] pimelate present in the SDS-soluble fraction as 
lipid intermediates was also decreased from 960 pmol/ 
mg protein in the control to 375 pmol and 242 pmol 
in the presence of 10 pg/ml and 20 I.cg/ml of tunica- 
mycin. Thus, tunicamycin appeared to inhibit the 
initial membrane bound step of peptidoglycan 
synthesis, the formation of undecaprenyl-P-P-N- 
acetylmuramyl pentapeptide. 
Confirmation of this was obtained when membrane 
preparations of both B. licheniformis 94 and the 
other organisms listed in table 1 were assayed for 
phospho-N-acetylmuramyl pentapeptide translocase 
activity. In each organism the translocase was inhibited 
by tunicamycin measured ineither the exchange or 
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transfer assays (table 1). Using membrane preparations 
isolated strains of B. examined, 
inhibition enzyme was at 
concentrations higher those 
to growth the situa- 
was in licheniformis ‘*cteus 
S. H. differences in three 
between amount antibiotic 
to growth translocase may 
reflect difference the of antibiotic 
reach interact the enzyme. 
the resistance the cocci 
B. 94 autolysis allow 
organisms survive inhibiting of 
mycin. role autolysins the 
effects other known inhibit 
stages peptidoglycan has been 
documented 121. 
I I I 
0 10 20 
Tunicamycin (us/ml ) 
Fig.1. Effect of tunicamycin on the incorporation of N-acetyl- 
muramyl-[sH]A,pm pentapeptide into peptidoglycan and 
[3H]glycerol phosphate into teichoic acid by a membrane + 
wall preparation of B. licheniformis 94. Radioactivity incorpo- 
rated into SDS-insoluble peptidoglycan (A) and teichoic acid 
(0) was determined. In the absence of antibiotic the 
membrane + wall preparation synthesized 1.44 nmol peptido- 
glycan and 1.93 nmol teichoic acid. 
Formation of the second lipid intermediate 
involved in peptidoglycan synthesis requires the 
transfer of N-acetylglucosamine from UDP-N-acetyl 
glucosamine toundecaprenyl-P-P-N-acetylmuramyl 
pentapeptide. The following experiment was carried 
out to determine whether this stage of peptidoglycan 
synthesis i  inhibited by tunicamycin. Membranes 
(652 hg protein) from B. licheniformis 94 were incu- 
bated with UDP-MurAc- [3H] DAP-pentapeptide 
(22.4 nmol), for 10 min at 28°C to allow the forma- 
tion of undecaprenyl-P-P-IV-acetylmuramyl penta- 
peptide. At this time UDP-N-acetyl [14C]glucosamine 
Table 1 
The inhibition of growth and of the phospho-N-acetyhnuramyl pentapeptide translocase activity of 
membrane preparations by tunicamycin 
Organism 
Growth inhibitory 
concentrationa bg/ml) 
Phospho-N-acetylmuramyl pentapeptide translocase 
Rate of exchangeb Concentration giving 50% inhibition 
of activity (fig/ml) 
B. licheniformis 94 10.0 5.75 1.2 
B. subtilis 168 0.2 4.92 1.5 
B. subtilis W23 0.5 4.54 1.4 
M. luteus 50.0 8.98 3.8 
S. aureus H > 50.0 7.10 5.2 
a The concentration of tunicamycin required to inhibit overnight growth of the organism in tryptone-yeast extract-glucose 
medium from an inoculum of lo4 bacteria/ml 
b The rate of exchange calculated as described [ 101 given in mol/litre/min X lo6 
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(16.3 nmol) was added in the presence or absence 
of tunicamycin (25 p&/ml). After a further 5 min 
incubation the reaction was stopped by the addition 
of chloroform-methanol. Lipid intermediates con- 
taining 14C but only negligible amounts of 3H were 
extracted with the organic phase. After removal of 
the chloroform the aqueous phases were dried in 
vacua, resuspended in water (0.5 ml) and peptido- 
glycan lipid intermediates extracted with butan-l-ol- 
pyridinium acetate. This procedure solubilised 
936.4 pmol and 776.1 pmol of 3H and 57.4 pmol 
and 5 1.3 pmol of 14C from the membranes incubated 
in the absence and presence of tunicamycin. 
Hence, tunicamycin reduced the amount of 14C 
present by 12% and that of 3H by 17%. Finally the 
aqueous phases were concentrated and the residues 
subject to chromatography. The peptidoglycan 
synthesized contained 90.8 pmol and 67.9 pmol of 
3H, with essentially equimolar amounts of 14C in 
each case. Thus, the formation of the second lipid 
intermediate, undecaprenyl-P-P-N-acetylmuramyl- 
(pentapeptide)-N-acetylglucosamine and the poly- 
merization of disaccharide-pentapeptide units are not 
markedly inhibited by tunicamycin. Clearly, the site 
of inhibition of peptidoglycan synthesis by this anti- 
biotic is the phospho-N-acetylmuramyl pentapeptide 
translocase. Recently Lehle and Tanner [3] have 
shown that tunicamycin inhibits the synthesis of 
dolichyl-P-P-N-acetylgiucosamine by membrane 
preparations of Saccharomyces cerevisiae but not 
the subsequent ransfer of a second residue of 
N-acetylglucosamine to this precursor. Thus in 
both systems tunicamycin inhibits the phospho- 
translocase reaction but not the N-acetylglucosaminyl 
transferase. 
The inhibition by tunicamycin of the synthesis of 
Nacetylglucosamine-containing lipid intermediates in 
bacilli may reflect a similar situation [7] . Low 
concentrations of tunicamycin (2 pg/ml) inhibited 
the formation by membranes of B. licheniformis 94 
of chloroform-methanol extractable IV-acetyl [‘“Cl 
glucosamine by 60.4%. Membranes incubated in the 
absence of antibiotic incorporated 829 pmol/mg 
protein. At higher antibiotic concentrations (10 pg/ 
ml and 20 pg/ml) inhibition increased only to 77%. The 
transfer of furtherNacetylglucosaminy1 residues to 
endogenous undecaprenyl-P-P-N-acetylglucosamine and 
its higher analogues may explain the residual 23% 
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incorporation [7]. Although the role of such lipid 
intermediates in biosynthesis remains unclear the 
involvement of such precursors has been described 
in the synthesis of membrane glycoproteins by 
B. licheniformis 9945A [ 131. In addition the tunica- 
mycin-sensitivity of teichoic acid biosynthesis in 
S. aureus [14,15] B. subtilis W23 [15,16] and 
B. licheniformis 94 suggests the involvement of 
N-acetylglucosamine-containing lipid intermediates 
in this process. 
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